| Literature DB >> 35661149 |
Hirotaka Kinoshita1, Daiki Takekawa2, Takashi Kudo2, Kaori Sawada3, Tatsuya Mikami4, Kazuyoshi Hirota2.
Abstract
Relationships between the neutrophil-lymphocyte ratio (NLR) and/or the platelet-lymphocyte ratio (PLR) and neuroinflammatory diseases have been reported. Depression is also associated with neuroinflammation. Here, we determined the association between the NLR, PLR, and depressive symptoms. This cross-sectional study is a secondary analysis of the data of the Iwaki Health Promotion Project 2017. We analyzed the characteristics and laboratory data of 1,015 Japanese subjects (597 females, 408 males) including their NLR and PLR values. We assigned the subjects with a Center for Epidemiologic Studies Depression Scale (CES-D) score ≥ 16 to the depressive symptoms group. We performed a multivariate logistic regression analysis to determine whether the NLR and/or PLR were associated with depressive symptoms (CES-D ≥ 16). Two hundred subjects (19.7%; 122 [20.4%] females, 78 [19.1%] males) were assigned to the depressive symptoms group. There were significant differences between the non-depressive symptoms and depressive symptoms groups in the NLR [median (25th to 75th percentile): 1.54 (1.24, 1.97) vs. 1.76 (1.32, 2.37), P = 0.005] and the PLR [median (25th to 75th percentile): 123.7 (102.0, 153.9) vs. 136.8 (107.0, 166.5), P = 0.047] in males, but not in females. The multivariate logistic regression analysis demonstrated that the NLR was significantly associated with depressive symptoms in males (adjusted odds ratio: per 1 increase, 1.570; 95% confidence interval: 1.120-2.220; P = 0.009). In conclusion, our findings indicate that higher NLR may be associated with depressive symptoms in males.Entities:
Mesh:
Year: 2022 PMID: 35661149 PMCID: PMC9166769 DOI: 10.1038/s41598-022-13562-x
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.996
Figure 1Study population flowchart.
The subjects' characteristics.
| Males | Females | |||||
|---|---|---|---|---|---|---|
| Non-depressive symptoms | Depressive symptoms | Non-depressive symptoms | Depressive symptoms | |||
| n | 340 (81.3%) | 78 (18.7%) | – | 475 (79.6%) | 122 (20.4%) | – |
| Age, yrs | 55 (41, 67) | 50.5 (38, 67) | 0.179 0.228 | 56 (43, 66) | 54 (37, 66) | 0.179 0.373 |
| < 45 | 100 (29.4%) | 31 (39.7%) | 137 (28.8%) | 43 (35.2%) | ||
| 45 ≤ , < 65 | 136 (40.0%) | 24 (30.8%) | 202 (42.5%) | 42 (34.4%) | ||
| 65 ≤ , < 75 | 71 (20.9%) | 18 (23.1%) | 96 (20.2%) | 27 (22.1%) | ||
| 75 ≤ | 33 (9.7%) | 5 (6.4%) | 40 (8.4%) | 10 (8.2%) | ||
| Height, cm | 169.3 (164.4, 173.2) | 168.9 (163.9, 173.7) | 0.945 | 156.4 (151.9, 160.1) | 155.5 (151.6, 160.6) | 0.796 |
| BW, kg | 67.1 (60.9, 73.7) | 65.4 (60.5, 73.0) | 0.384 | 52.9 (48.1, 59.1) | 53.2 (48.7, 57.5) | 0.941 |
| BMI, kg/m2 | 23.5 (21.6, 25.8) | 23.4 (21.5, 25.2) | 0.422 0.376 | 22.0 (19.8, 24.2) | 22.0 (19.3, 24.7) | 0.864 0.375 |
| < 18.5 | 9 (2.6%) | 1 (1.3%) | 51 (10.7%) | 17 (13.9%) | ||
| 18.5 ≤ , < 25 | 218 (64.1%) | 57 (73.1%) | 330 (69.5%) | 76 (62.3%) | ||
| 25 ≤ , < 30 | 95 (27.9%) | 15 (19.2%) | 75 (15.8%) | 25 (20.5%) | ||
| 30 ≤ | 18 (5.3%) | 5 (6.4%) | 19 (4.0%) | 4 (3.3%) | ||
| CES-D | 6 (2, 10) | 19 (17, 24.8) | < 0.001* | 7 (3, 10) | 21 (18, 25) | <0.001* |
| AST, U/L | 23 (19, 29) | 23 (19, 27) | 0.768 | 20 (17, 24) | 19 (16, 23) | 0.070 |
| ALT, U/L | 21.5 (17, 31) | 22 (18, 30) | 0.683 | 16 (13, 20) | 14.5 (11, 19) | 0.083 |
| BUN, mg/dL | 14.7 (12.5, 17.8) | 14.7 (11.9, 17.1) | 0.395 | 13.5 (11.4, 16.1) | 13.4 (11.0, 16.8) | 0.806 |
| Cre, mg/dL | 0.83 (0.75, 0.92) | 0.81 (0.74, 0.91) | 0.563 | 0.61 (0.56, 0.67) | 0.61 (0.55, 0.67) | 0.992 |
| BNP, pg/dL | 6.2 (5.8, 11.1) | 6.5 (5.8, 10.6) | 0.754 | 9.4 (5.9, 15.1) | 10.0 (6.0, 16.3) | 0.832 |
| HbA1c, % | 5.6 (5.4, 5.8) | 5.6 (5.3, 5.9) | 0.353 | 5.8 (5.4, 5.8) | 5.6 (5.3, 5.8) | 0.578 |
| Hypertension | 106 (31.2%) | 21 (26.9%) | 0.498 | 115 (24.2%) | 34 (27.9%) | 0.413 |
| DM | 25 (7.4%) | 6 (7.7%) | 1.000 | 17 (3.6%) | 3 (2.5%) | 0.778 |
| Dyslipidemia | 42 (12.4%) | 9 (11.5%) | 1.000 | 56 (11.8%) | 17 (13.9%) | 0.536 |
| CAD | 8 (2.4%) | 0 (0%) | 0.361 | 7 (1.5%) | 1 (0.8%) | 1.000 |
| Stroke | 9 (2.6%) | 1 (1.3%) | 0.696 | 8 (1.7%) | 3 (2.5%) | 0.704 |
| Current smoker | 89 (26.2%) | 19 (24.4%) | 0.777 | 34 (7.2%) | 13 (10.7%) | 0.257 |
| Alcohol drinker | 245 (72.1%) | 45 (57.7%) | 0.020* | 156 (32.8%) | 37 (30.3%) | 0.665 |
*P < 0.05. Differences between the non-depressive symptoms and depressive symptoms groups were examined by Fisher's exact test for categorical variables and Mann–Whitney test for continuous variables. Data are shown as number (a percentage of each group) or median (25 to 75th percentile).
ALT alanine transferase, AST aspartate transferase, BMI body mass index, BNP B-type natriuretic peptide, BUN blood urea nitrogen, BW body weight, CAD coronary artery disease, CES-D Center for Epidemiologic Studies Depression Scale, Cre creatinine, DM diabetes mellitus, HbA1c hemoglobin A1c.
Relationships between depressive symptoms and NLR or PLR.
| Males | Females | |||||
|---|---|---|---|---|---|---|
| Non-depressive symptoms | Depressive symptoms | Non-depressive symptoms | Depressive symptoms | |||
| NLR | 1.54 (1.24, 1.97) | 1.76 (1.32, 2.37) | 0.005* | 1.49 (1.16, 1.97) | 1.56 (1.23, 2.03) | 0.373 |
| PLR | 123.7 (102.0, 153.9) | 136.8 (107.0, 166.5) | 0.047* | 139.4 (113.2, 173.0) | 135.0 (114.4, 165.8) | 0.801 |
*P < 0.05. Differences between the non-depressive symptoms and depressive symptoms groups were estimated by the Mann–Whitney test. Data are median (25th to 75th percentile), NLR: neutrophil–lymphocyte ratio, PLR: platelet-lymphocyte ratio.
Logistic regression analysis to identify whether NLR and PLR are associated with depressive symptoms.
| Males | Females | |||
|---|---|---|---|---|
| aOR (95%CI) | aOR (95%CI) | |||
| NLR, per 1 increase | 1.570 (1.120–2.220) | 0.009* | 0.871 (0.652–1.160) | 0.349 |
| PLR, per 1 increase | 1.000 (0.994–1.010) | 0.899 | 1.000 (0.997–10.10) | 0.520 |
| < 45 | Reference | Reference | ||
| 45 ≤ , < 65 | 0.546 (0.285, 1.050) | 0.069 | 0.668 (0.392, 1.140) | 0.137 |
| 65 ≤ , < 75 | 0.763 (0.344, 1.690) | 0.504 | 0.912 (0.463, 1.800) | 0.790 |
| 75 ≤ | 0.359 (0.111, 1.160) | 0.087 | 0.734 (0.289, 1.860) | 0.516 |
| 18.5 ≤ , < 25 | Reference | Reference | ||
| < 18.5 | 0.355 (0.043, 2.920) | 0.335 | 1.470 (0.780, 2.790) | 0.233 |
| 25 ≤ , < 30 | 0.674 (0.352, 1.290) | 0.235 | 1.400 (0.812, 2.420) | 0.225 |
| 30 ≤ | 0.837 (0.279, 2.510) | 0.751 | 0.822 (0.258, 2.620) | 0.741 |
| AST, per 1 U/L increase | – | 0.951 (0.900–1.010) | 0.077 | |
| ALT, per 1 U/L increase | – | 1.020 (0.986–1.050) | 0.247 | |
| Hypertension | 1.060 (0.523–2.130) | 0.881 | 1.340 (0.766–2.340) | 0.305 |
| DM | 1.030 (0.355–2.960) | 0.964 | 0.565 (0.151–2.110) | 0.397 |
| Dyslipidemia | 1.080 (0.446–2.600) | 0.871 | 1.360 (0.706–2.630) | 0.357 |
| CAD | – | 0.476 (0.056–4.040) | 0.496 | |
| Stroke | 1.000 (1.000–1.000) | 0.551 | 1.000 (1.000–1.000) | 0.596 |
| Alcohol drinker | 0.548 (0.322–0.930) | 0.026* | ||
*P < 0.05. As none of the VIF values were up to 10, there was no collinearity in the model. AUC values for males and females were 0.675 and 0.603, respectively. Hosmer–Lemeshow test: P = 0.36, which means that the fitness of this model was good.
aOR adjusted odds ratio, ALT alanine transferase, AST aspartate transferase, BMI body mass index, CAD coronary artery disease, DM diabetes mellitus, NLR neutrophil–lymphocyte ratio, PLR platelet-lymphocyte ratio.